Results 1 to 10 of about 317,819 (360)

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort [PDF]

Haematologica, 2019
Myeloid and lymphoid malignancies are postulated to have distinct pathogenetic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancy has challenged this ...
Johanne M. Holst, Trine L. Plesner, Martin B. Pedersen, Henrik Frederiksen, Michael B. Møller, Michael R. Clausen, Marcus C. Hansen, Stephen Jacques Hamilton-Dutoit, Peter Nørgaard, Preben Johansen, Tobias Ramm Eberlein, Bo K. Mortensen, Gustav Mathiasen, Andreas Øvlisen, Rui Wang, Chao Wang, Weiwei Zhang, Hans Beier Ommen, Jesper Stentoft, Maja Ludvigsen, Wayne Tam, Wing C. Chan, Giorgio Inghirami, Francesco d'Amore   +23 more
doaj   +4 more sources

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases [PDF]

American journal of hematology/oncology, 2021
Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting.
N. Gangat, P. Guglielmelli, N. Szuber, K. Begna, M. Patnaik, M. Litzow, A. Al-Kali, J. Foran, J. Palmer, H. Alkhateeb, M. Elliott, C. Hanson, A. Pardanani, F. Mannelli, A. Vannucchi, A. Tefferi   +15 more
semanticscholar   +3 more sources

Myelodysplastic/Myeloproliferative Neoplasms [PDF]

American Journal of Clinical Pathology, 2009
AbstractMyelodysplastic/myeloproliferative neoplasms (MDS/MPNs) are rare de novo myeloid neoplasms that exhibit hybrid dysplastic and proliferative features at presentation. This SHP/EAHP Workshop session was uniquely problematic owing to the overlap between MDS/MPNs and both chronic myeloproliferative neoplasms and myelodysplasia.
Kathryn Foucar
openalex   +4 more sources

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts [PDF]

Leukemia, 2018
A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from the Mayo Clinic and 162 from Italy. Median survival was 3.6 months, with no improvement over the last 15 years. Multivariable analysis
A. Tefferi, M. Mudireddy, F. Mannelli, K. Begna, M. Patnaik, C. Hanson, R. Ketterling, N. Gangat, Meera Yogarajah, V. De Stefano, F. Passamonti, V. Rosti, M. Finazzi, A. Rambaldi, A. Bosi, P. Guglielmelli, A. Pardanani, A. Vannucchi   +17 more
semanticscholar   +5 more sources

Histopathology imagery dataset of Ph-negative myeloproliferative neoplasm [PDF]

Data in Brief, 2023
Tumorous cancer has been a widely known and well-studied medical phenomenon; however, rare diseases like Myeloproliferative Neoplasm (MPN) have received less attention, leading to delayed diagnosis.
Umi Kalsom Mohamad Yusof, Syamsiah Mashohor, Marsyita Hanafi, Sabariah Md Noor, Norsafina Zainal   +4 more
doaj   +2 more sources

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms [PDF]

Histopathology, 2020
AimsRenal changes in patients with myeloproliferative neoplasms (MPNs) or myelodysplastic syndrome (MDS)/MPNs have been addressed by few, respectively no, reports. The aim of this study was to focus on a systematic evaluation of renal biopsies in patients with MPNs or MDS/MPNs.Methods and resultsThe cohort comprised 29 patients (23 men) aged 67 ± 11 ...
Maike Büttner‐Herold, Carsten Sticht, Thorsten Wiech, Stefan Porubsky   +3 more
openaire   +8 more sources

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency

Haematologica, 2016
Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation.
Zohar Sachs, Raha A. Been, Krista J. DeCoursin, Hanh T. Nguyen, Nurul A. Mohd Hassan, Klara E. Noble-Orcutt, Craig E. Eckfeldt, Emily J. Pomeroy, Ernesto Diaz-Flores, Jennifer L. Geurts, Miechaleen D. Diers, Diane E. Hasz, Kelly J. Morgan, Margaret L. MacMillan, Kevin M. Shannon, David A. Largaespada, Stephen M. Wiesner   +16 more
doaj   +2 more sources

Deactylase inhibition in myeloproliferative neoplasms [PDF]

Investigational New Drugs, 2010
Myeloproliferative neoplasms (MPN) are clonal haemopoietic progenitor cell disorders characterized by the proliferation of one or more of the haemopoietic lineages (myeloid, erythroid and/or megakaryocytic). The MPNs include eight haematological disorders: chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET ...
Sridurga Mithraprabhu, George Grigoriadis, Tiffany Khong, Andrew Spencer   +3 more
openalex   +5 more sources

Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice‐site CBL variant alongside a novel constitutional CSF3R variant [PDF]

eJHaem
Casitas B‐cell lineage (CBL) syndrome is a rare RASopathy known to predispose to CBL‐mutated juvenile myelomonocytic leukemia (JMML) in childhood. Adulthood acute myeloid leukemia arising out of a genetic aberrancies consistent with prior CBL‐mutated ...
George Mason, Rhian Aghajani, Brieanna Dance, Jad Othman, Linda Goodwin, William Stevenson, Naomi Mackinlay   +6 more
doaj   +2 more sources

The <i>JAK2_V617F</i> mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden. [PDF]

EJHaem, 2023
Funding information: MPNVoice,Grant/AwardNumber:0001 Acknowledgements: The authors would like to express gratitude to the participants who gave their time to take part in the MOSAICC pilot study.
Orbell LY, Abutheraa N, Duncombe AS, McMullin MF, Mesa R, McShane CM, James G, Anderson LA.   +7 more
europepmc   +3 more sources